Test article for multiple authors

In the study through 76 weeks, no new risks were observed with once-daily upadacitinib (15 mg or 30 mg).

If approved, SL1009 has the potential to be the first approved medication for PDCD, and would be available as an oral solution.

Colleen Sloan, PA-C, RDN, details how technology can affect eye health in children and identifies which nutrients can help mitigate its effect.

Mike Hennessy Jr. shares his thoughts on the holiday health paradox.